Today’s Stock Alert: How Analysts Feel About Pacific Biosciences of California After Today’s Huge Decline?

Today's Stock Alert: How Analysts Feel About Pacific Biosciences of California After Today's Huge Decline?

The stock of Pacific Biosciences of California (NASDAQ:PACB) is a huge mover today! About 1.32 million shares traded hands or 33.70% up from the average. Pacific Biosciences of California (NASDAQ:PACB) has risen 5.97% since March 8, 2016 and is uptrending. It has underperformed by 3.34% the S&P500.
The move comes after 6 months negative chart setup for the $792.10M company. It was reported on Oct, 11 by Barchart.com. We have $8.03 PT which if reached, will make NASDAQ:PACB worth $39.61M less.

Analysts await Pacific Biosciences of California (NASDAQ:PACB) to report earnings on October, 27. They expect $-0.19 earnings per share, up 29.63% or $0.08 from last year’s $-0.27 per share. After $-0.21 actual earnings per share reported by Pacific Biosciences of California for the previous quarter, Wall Street now forecasts -9.52% EPS growth.

Pacific Biosciences of California (NASDAQ:PACB) Ratings Coverage

Out of 5 analysts covering Pacific Biosciences of California (NASDAQ:PACB), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Pacific Biosciences of California has been the topic of 10 analyst reports since August 27, 2015 according to StockzIntelligence Inc. The stock of Pacific Biosciences of California (NASDAQ:PACB) earned “Neutral” rating by Piper Jaffray on Thursday, February 4. The rating was upgraded by Piper Jaffray on Friday, October 23 to “Overweight”. The stock of Pacific Biosciences of California (NASDAQ:PACB) has “Overweight” rating given on Friday, April 15 by First Analysis. The firm has “Buy” rating given on Thursday, August 27 by Maxim Group. The stock of Pacific Biosciences of California (NASDAQ:PACB) earned “Buy” rating by CL King on Monday, June 27. The stock of Pacific Biosciences of California (NASDAQ:PACB) earned “Neutral” rating by M Partners on Friday, April 15. On Thursday, August 27 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The stock of Pacific Biosciences of California (NASDAQ:PACB) earned “Buy” rating by Cantor Fitzgerald on Monday, January 4.

According to Zacks Investment Research, “Pacific Biosciences of California, Inc. is engaged in the development, manufacture and commercialization of its single molecule, real-time, or SMRT technology-an integrated platform for genetic analysis. The SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events as they occur. The Company’s technology platform comprises of the SMRT cells, Phospholinked nucleotides and the PacBio RS (an instrument that conducts, monitors and analyzes single molecule biochemical reactions in real time). Its product will find its application in both research institutions and commercial companies, including genome centers, government and academic institutions, genomic service providers, pharmaceutical companies and agriculture companies. Pacific Biosciences of California, Inc. is headquartered in Menlo Park, California.”

Insitutional Activity: The institutional sentiment increased to 2.12 in Q2 2016. Its up 0.36, from 1.76 in 2016Q1. The ratio is positive, as 15 funds sold all Pacific Biosciences of California shares owned while 26 reduced positions. 25 funds bought stakes while 62 increased positions. They now own 60.55 million shares or 5.09% more from 57.62 million shares in 2016Q1.
Fuller Thaler Asset Mgmt has 400,639 shares for 0.05% of their US portfolio. Millennium Management Ltd Liability Corp owns 3.61M shares or 0.06% of their US portfolio. Panagora Asset, a Massachusetts-based fund reported 676,901 shares. Stevens Capital Mngmt Lp holds 0% of its portfolio in Pacific Biosciences of California (NASDAQ:PACB) for 14,801 shares. Teachers Advsr owns 817,791 shares or 0.01% of their US portfolio. Pnc Financial Ser Gru holds 0% or 380 shares in its portfolio. Tocqueville Asset L P last reported 25,000 shares in the company. Spot Trading Limited Liability last reported 0% of its portfolio in the stock. Axa owns 172,300 shares or 0.01% of their US portfolio. Bnp Paribas Arbitrage Sa last reported 2,961 shares in the company. Ing Groep Nv has invested 0.01% of its portfolio in Pacific Biosciences of California (NASDAQ:PACB). Geode Capital Mgmt Ltd Company holds 0% of its portfolio in Pacific Biosciences of California (NASDAQ:PACB) for 487,267 shares. Moreover, Jpmorgan Chase & has 0% invested in Pacific Biosciences of California (NASDAQ:PACB) for 54,910 shares. The New York-based Gilder Gagnon Howe And Limited Liability Company has invested 0.44% in Pacific Biosciences of California (NASDAQ:PACB). Hbk L P accumulated 168,500 shares or 0.01% of the stock.

Insider Transactions: Since April 25, 2016, the stock had 0 insider buys, and 2 insider sales for $374,640 net activity. Phillips James Michael had sold 20,000 shares worth $205,720 on Monday, April 25.

More notable recent Pacific Biosciences of California (NASDAQ:PACB) news were published by: Prnewswire.com which released: “Research Reports Initiation on Biotech Stocks — Pacific Biosciences of …” on October 10, 2016, also Fool.com with their article: “Why Shares of Pacific Biosciences of California Spiked 19% Today” published on April 22, 2016, Prnewswire.com published: “Dovetail Genomics Adds PacBio SMRT Sequencing and Assembly to Its Services Menu” on September 22, 2016. More interesting news about Pacific Biosciences of California (NASDAQ:PACB) were released by: Fool.com and their article: “Pacific Biosciences of California Doubles Revenue in Q4” published on February 04, 2016 as well as Fool.com‘s news article titled: “Why Pacific Biosciences of California Inc Is Down Big Today” with publication date: January 11, 2016.

PACB Company Profile

Pacific Biosciences of California, Inc., incorporated in July 14, 2000, designs, develops and makes sequencing systems to help scientists resolve genetically complex problems. The Company’s Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company has introduced the PacBio RS II System. Based on the Company’s SMRT sequencing technology, its products enable de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to characterize genetic variations, and deoxyribonucleic acid (DNA) base modification identification to help characterize epigenetic regulation and DNA damage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment